Dobrican-Băruța, C.-T.; Deleanu, D.M.; Muntean, I.A.; Pintea, I.; Florea, C.M.; Filip, G.A. IL-31—Pruritus Interleukin: Serum Values and Clinical Impact in Chronic Spontaneous Urticaria—A Romanian Retrospective Study. J. Clin. Med.2023, 12, 5957.
Dobrican-Băruța, C.-T.; Deleanu, D.M.; Muntean, I.A.; Pintea, I.; Florea, C.M.; Filip, G.A. IL-31—Pruritus Interleukin: Serum Values and Clinical Impact in Chronic Spontaneous Urticaria—A Romanian Retrospective Study. J. Clin. Med. 2023, 12, 5957.
Dobrican-Băruța, C.-T.; Deleanu, D.M.; Muntean, I.A.; Pintea, I.; Florea, C.M.; Filip, G.A. IL-31—Pruritus Interleukin: Serum Values and Clinical Impact in Chronic Spontaneous Urticaria—A Romanian Retrospective Study. J. Clin. Med.2023, 12, 5957.
Dobrican-Băruța, C.-T.; Deleanu, D.M.; Muntean, I.A.; Pintea, I.; Florea, C.M.; Filip, G.A. IL-31—Pruritus Interleukin: Serum Values and Clinical Impact in Chronic Spontaneous Urticaria—A Romanian Retrospective Study. J. Clin. Med. 2023, 12, 5957.
Abstract
(1) Background: This study aimed to evaluate the implications of IL-31 in the pathogenesis of chronic spontaneous urticaria (CSU) and to assess the differences that occur between its serum values compared to controls. Additionally, the serum IL-31 levels were measured alongside other clinical and paraclinical parameters identified in the patients to understand its immunological importance in this skin disease and to determine if it could potentially serve as a therapeutic target in CSU in the future. (2) Methods: The serum levels of IL-31 were estimated in 50 patients diagnosed with CSU according to the international guidelines. Additionally, 38 controls who had not experienced any episodes of urticaria during their lifetime were included. (3) Results: Our data have shown higher serum levels of IL-31 in CSU patients compared to controls. A correlation between the serum level of IL-31 and other inflammatory markers, such as ERS, CRP, or serum eosinophils and total IgE was not identified. On the other hand, statistically significant differences were found in IL-31 serum values in UCS patients depending on the severity of the disease, its impact on the patients' quality of life, the severity of itching, and the response to H1 antihistamines. (4) Conclusions: In the present study, IL-31 did not change directly with non-specific inflammation, nor with eosinophilic inflammation or atopy. However, its expression was modified in CSU depending on major characteristics of the disease: severity, pruritus, and response to H1 antihistamines. The focus on the pathogenesis of CSU is of indisputable significance since any additional information in understanding the mechanisms of this disease can open doors to new therapeutic targets. This is particularly important considering that the available therapies are deficient, incomplete, and the remaining symptoms are uncontrolled in many cases.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
*
